Boundless Bio, Inc. BOLD
Set alert
2.44 USD 0.00 -0.20%
As of Nov 3, 10:48 AM ET
2.43 Day range 2.55
0.961 52-week range 3.16
- YTD
- +102.92%
- 1 year
- +77.74%
- Open
- 2.44
- Prev close
- 2.44
- Mkt cap
- 56.29M
- Vol
- 9.29K
- Avg vol
- 174.56K
- EPS
- -2.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.43
- High
- 2.55
- Forward P/E
- -0.70
- Beta
- 0.00
- Short ratio
- 2.01
- Inst. own
- 75.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 6, 2025
- 50-d avg
- 2.91
- 200-d avg
- 5.46
- 1y target
- 14.50
YTD chart
Signals (39)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| RSI: Oversold | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| RSI: Overbought | Aug 18, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| RSI: Overbought | Aug 4, 2026 | 3 months ago |
| RSI: Overbought | Jul 24, 2026 | 3 months ago |
| RSI: Overbought | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| RSI: Overbought | Jun 23, 2026 | 4 months ago |
| SMA: Bearish | Jun 9, 2026 | 4 months ago |
| MACD: Sell Signal | Apr 28, 2026 | 6 months ago |
| RSI: Overbought | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
Newest 20 of 39.
Analyst view
Consensus: buy
Buy
Price target (mean) 14.50 +495.5% upside
Now 2.44
- Target (low)
- 14.00
- Target (mean)
- 14.50
- Target (high)
- 15.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.78333 | -0.83 – -0.74 | 0.00 | 0.0% | 0 | 0.0% | 3 |
| Next quarter | -0.77 | -0.78 – -0.76 | -12.27 | +93.7% | 0 | 0.0% | 3 |
| Current year | -7.46 | -14.61 – -3.86 | 0.00 | 0.0% | 0 | 0.0% | 3 |
| Next year | -3.39 | -3.62 – -3.18 | -7.46 | +54.6% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| Apr 22, 2024 | Leerink Partners | Initiated | — | Outperform |
| Apr 22, 2024 | Guggenheim | Initiated | — | Buy |
| Apr 22, 2024 | Piper Sandler | Initiated | — | Overweight |